LZTS2 and non-small cell lung carcinoma: Emerging studies have demonstrated that the expression of LZTS2 is attenuated or even lost in numerous malignant tumors, such as prostate cancer, non-small cell lung cancer (NSCLC) and colon cancer [26–28].